Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF
| Autor: | Akshay S. Desai, Margaret F. Prescott, Søren Lund Kristensen, Pardeep S. Jhund, Michele Senni, Andrej Dukát, Scott D. Solomon, John J.V. McMurray, Felix J. A. Ramires, Victor Shi, Milton Packer, Lars Køber, Chen Huan Chen, Martin Lefkowitz, Karl Swedberg, Jean L. Rouleau, Ulrik M. Mogensen |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Ejection fraction business.industry Hazard ratio Renal function 030204 cardiovascular system & hematology medicine.disease Sacubitril 03 medical and health sciences 0302 clinical medicine Valsartan Internal medicine Heart failure Cardiology Medicine 030212 general & internal medicine Enalapril Cardiology and Cardiovascular Medicine business Sacubitril Valsartan medicine.drug |
| Zdroj: | European Journal of Heart Failure. 20:514-522 |
| ISSN: | 1388-9842 |
| DOI: | 10.1002/ejhf.1056 |
| Popis: | Aims: Elevated serum uric acid concentration (SUA) has been associated with an increased risk of cardiovascular disease, but this may be due to unmeasured confounders. We examined the association between SUA and outcomes as well as the effect of sacubitril/valsartan on SUA in patients with heart failure with reduced ejection fraction (HFrEF) in PARADIGM-HF. Methods and results: The association between SUA and the primary composite outcome of cardiovascular death or heart failure (HF) hospitalization, its components, and all-cause mortality was examined using Cox regression analyses among 8213 patients using quintiles (Q1–Q5) of SUA adjusted for baseline prognostic variables including estimated glomerular filtration rate (eGFR), diuretic dose, and log N-terminal pro-brain natriuretic peptide. Change in SUA from baseline over 12 months was also evaluated in each treatment group. Patients in Q5 (SUA ≥8.6 mg/dL) compared with Q1 ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text